Health · Pharma & Biotech · 12 hrs ago

South Korea approved 203 biopharmaceutical trials through September

South Korea approved 203 biopharmaceutical trials through September

South Korea approved 203 biopharmaceutical trials from January through September 2026.

Approvals rose each quarter, from 53 in the first quarter to 61 in the second and 89 in the third.

In the third quarter, 78 of the 89 trials involved multiple countries, while 11 were conducted in one country.

More than half of third-quarter approvals were for late-stage Phase 3 trials, which test treatments in larger groups of people.

Antibody medicines made up nearly three-quarters of the quarter’s trials, and cancer studies were the largest treatment area.

The figures cover approved trials in South Korea, but exclude studies where a biopharmaceutical was only a control or supporting treatment, as well as researcher-led and extension trials.

The association began publishing these quarterly figures this year, and the available figures go through September.

1 source

Related

What people are saying

Korea Biopharmaceutical AssociationIndustry association
Participation in early-phase trials continued, alongside large-scale late-phase trials.
via Yonhap